NCT07899099Recruiting
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
A Real-World Study of Mecapegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 6 Sept 2026
- Start date
- 24 Oct 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Zheng Yabing
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07899099
What you commit to
- Study type: Observational
- Planned participants: 200
- From 24 Oct 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Early-stage breast cancer.
- Any condition or other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment.
Other
- Ongoing systemic anticancer treatment without a need to change to a new treatment regimen.
- Pregnant or breastfeeding women.
Who the study is looking for
- Age 18 years or older.
- Histologically confirmed advanced breast cancer, defined as locally recurrent disease not suitable for curative treatment or metastatic disease.
- First recurrence or metastasis, or documented disease progression during palliative treatment, with a planned new systemic anticancer treatment regimen.
- Estimated life expectancy of at least 3 months.
- Ability and willingness to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.